Novartis AG's Earnings Report Highlights

Core Insights - Novartis AG reported an earnings per share (EPS) of $2.25, slightly below the expected $2.26, but achieved a revenue of approximately $13.9 billion, surpassing the estimated $13.8 billion, driven by strong sales of key drugs [2] - The company's third-quarter net profit increased significantly to $3.93 billion, aided by higher sales of its key drugs, which helped mitigate the financial impact of patent expirations [3] - Novartis's price-to-earnings (P/E) ratio is approximately 26.16, indicating the market's valuation of its earnings [3] Financial Ratios - The price-to-sales ratio is about 4.59, and the enterprise value to sales ratio is around 5.07, reflecting the company's strong market position [4] - The enterprise value to operating cash flow ratio is approximately 13.32, indicating cash flow efficiency [4] - The earnings yield stands at about 3.82%, providing insight into the return on investment [4] - The debt-to-equity ratio is approximately 0.78, showing a balanced approach to financing [4] - The current ratio is around 0.82, suggesting the company's capability to cover short-term liabilities with short-term assets [4]